سعر فيبا 10000 وحدة دولية/20 مل فيال وريد 1000 units/20 مل 2026

FEIBA (anti-inhibitor coagulant complex) 1000 units powder for solution for intravenous infusion, with 20 ml solvent (Takeda), 1 vial.

• Haemophilia A and B patients with inhibitors: control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes. Not for bleeding due to factor deficiencies without inhibitors.Population: Patients with haemophilia A or B with inhibitorsDailyMed (U.S. National Library of Medicine)

• Most frequent (>5% in the prophylaxis trial): anaemia, diarrhoea, haemarthrosis, hepatitis B surface antibody positive, nausea and vomiting. Serious: hypersensitivity reactions and thromboembolic events (stroke, pulmonary embolism, deep vein thrombosis).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known anaphylactic or severe hypersensitivity reactions to FEIBA or its components (including factors of the kinin-generating system); disseminated intravascular coagulation (DIC); acute thrombosis or embolism (including myocardial infarction).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Thromboembolic events (DIC, venous thrombosis, pulmonary embolism, myocardial infarction, stroke) can occur, particularly above 200 units/kg/day or with thrombotic risk factors; monitor patients receiving more than 100 units/kg for DIC, acute coronary ischaemia and other thromboembolic events.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Thrombotic microangiopathy was reported when FEIBA was used for breakthrough bleeding in patients on emicizumab prophylaxis; anaphylaxis/severe hypersensitivity may occur; made from human plasma, so it may carry a risk of transmitting infectious agents.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Systemic antifibrinolytics (tranexamic acid, aminocaproic acid)Possible thrombotic events; use of antifibrinolytics within approximately 6 to 12 hours after FEIBA is not recommended.DailyMed (U.S. National Library of Medicine)
• EmicizumabThrombotic microangiopathy and thromboembolic events reported; weigh benefits/risks and monitor closely if FEIBA is required.DailyMed (U.S. National Library of Medicine)

• No data with FEIBA use in pregnant women; animal reproduction studies have not been conducted.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No information on presence in human milk or effects on the breastfed child; weigh benefits of breastfeeding against the mother's need for FEIBA.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Factor VIII inhibitor bypassing activity (anti-inhibitor coagulant complex): Freeze-dried human plasma fraction containing prothrombin-complex factors (II, IX, X mainly non-activated; VII mainly activated) that generate thrombin and bypass factor VIII/IX inhibitors.